Difference between revisions of "Part:BBa K1993008"
Line 59: | Line 59: | ||
<tr> | <tr> | ||
<td><img src="https://static.igem.org/mediawiki/2016/7/78/T--SYSU-MEDICINE--BBa_K1993008-fig6.png" style="width:300px" ></a></td> | <td><img src="https://static.igem.org/mediawiki/2016/7/78/T--SYSU-MEDICINE--BBa_K1993008-fig6.png" style="width:300px" ></a></td> | ||
− | <td><img src="https://static.igem.org/mediawiki/2016/c/c4/T--SYSU-MEDICINE--BBa_K1993008-fig7.png" style="width: | + | <td><img src="https://static.igem.org/mediawiki/2016/c/c4/T--SYSU-MEDICINE--BBa_K1993008-fig7.png" style="width:100px" ></a></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
Line 79: | Line 79: | ||
<html> | <html> | ||
<img src="https://static.igem.org/mediawiki/2016/7/7e/T--SYSU-MEDICINE--BBa_K1993008-fig8.png" style="height:200px"></a> | <img src="https://static.igem.org/mediawiki/2016/7/7e/T--SYSU-MEDICINE--BBa_K1993008-fig8.png" style="height:200px"></a> | ||
− | <html> | + | </html> |
− | ''' | + | |
+ | <br> | ||
+ | '''Figure8''' | ||
<br> | <br> | ||
− | Figure8 :The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that | + | Figure8 :The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that MSC<sup>CXCR5</sup> exhibited enhanced capacities for targeted migration to the ears in DTH model. |
Line 89: | Line 91: | ||
<html> | <html> | ||
<img src="https://static.igem.org/mediawiki/2016/7/74/T--SYSU-MEDICINE--BBa_K1993008-fig9.png" style="height:200px"></a> | <img src="https://static.igem.org/mediawiki/2016/7/74/T--SYSU-MEDICINE--BBa_K1993008-fig9.png" style="height:200px"></a> | ||
− | <html><br> | + | </html> |
− | + | <br> | |
− | The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed | + | |
+ | '''Figure9''' | ||
+ | |||
+ | <br> | ||
+ | The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed MSC<sup>CXCR5</sup> could be located in the inflamed ears of DTH mice. | ||
<br> | <br> | ||
Line 101: | Line 107: | ||
<img src="https://static.igem.org/mediawiki/2016/0/0d/T--SYSU-MEDICINE--BBa_K1993008-fig10.png" style="width:300px" ></a> | <img src="https://static.igem.org/mediawiki/2016/0/0d/T--SYSU-MEDICINE--BBa_K1993008-fig10.png" style="width:300px" ></a> | ||
</html> | </html> | ||
− | < | + | |
− | '''Figure | + | <br> |
+ | '''Figure 10''' | ||
<br> | <br> | ||
− | Ear sampling for quantitative PCR analysis. Compared with DTH+MSCs group, levels of anti-inflammatory cytokines (IL-10) elevated in DTH+ | + | Ear sampling for quantitative PCR analysis. Compared with DTH+MSCs group, levels of anti-inflammatory cytokines (IL-10) elevated in DTH+MSC<sup>CXCR5</sup> group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSC<sup>CXCR5</sup> group. |
− | '''In a word, | + | '''In a word, MSC<sup>CXCR5</sup> displayed greater immunoregulatory effect.''' |
<li><br> | <li><br> | ||
Line 111: | Line 118: | ||
<img src="https://static.igem.org/mediawiki/2016/7/79/T--SYSU-MEDICINE--BBa_K1993008-fig11.png" style="width:300px" ></a> | <img src="https://static.igem.org/mediawiki/2016/7/79/T--SYSU-MEDICINE--BBa_K1993008-fig11.png" style="width:300px" ></a> | ||
</html> | </html> | ||
+ | <br> | ||
'''Figure 11''' | '''Figure 11''' | ||
+ | |||
<br> | <br> | ||
<html> | <html> | ||
<img src="https://static.igem.org/mediawiki/2016/c/c6/T--SYSU-MEDICINE--BBa_K1993008-fig12.png" style="width:300px" ></a> | <img src="https://static.igem.org/mediawiki/2016/c/c6/T--SYSU-MEDICINE--BBa_K1993008-fig12.png" style="width:300px" ></a> | ||
</html> | </html> | ||
− | < | + | <br> |
'''Figure 12''' | '''Figure 12''' | ||
<br> | <br> | ||
− | After injection, | + | After injection, MSC<sup>CXCR5</sup> displayed better treatment efficacy than MSCeGFP, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSC<sup>CXCR5</sup> significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection. |
− | '''In a word, | + | '''In a word, MSC<sup>CXCR5</sup> regulated immune system in inflammatory condition in a more significant way.''' |
− | + | ||
+ | <br> | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Revision as of 12:31, 17 October 2016
Luciferase-IRES-eGFP
Functions:
With the purpose of increasing homing efficiency of MSCs and illustrating their distribution, we constructed a plasmid BBa_K1993008 under the control of EF-1α. (Figure 1) After that, plasmid BBa_K1993008 would be transduced into MSCs by lentivirus expression vector. What’s more, we confirmed its function in vitro and in vivo (DTH).
Figure 1 EF-1α-CXCR5-IRES-eGFP
Details:
- Elongation factor-1α (EF-1α), a constitutive promoter, is responsible for mediating the recruitment of aminoacyl-tRNA to the A-site of the 80S ribosome during protein synthesis.
- CXCR5 is a chemokine receptor and its corresponding ligand is CXCL13. (Details could be seen on BBa_K1993013)
- Internal ribosome entry site (IRES) is an RNA element that allows for translation initiation in an end-independent manner, as part of the greater process of protein synthesis. (Details could be seen on BBa_K1993016)
- LeGFP dramatically improved the spectral characteristics of GFP and allowed the practical use of GFPs in mammalian cells. (Details could be seen on BBa_K1993017)
Results:
In vitro
-
Figure 2 Figure 3 -
Figure 4 Figure 5 -
Figure 6 Figure 7
In vivo
Figure8
Figure8 :The inflamed ears were collected from each group and subjected to in situ immunofluorescence staining. Our results revealed that MSCCXCR5 exhibited enhanced capacities for targeted migration to the ears in DTH model.
Figure9
The inflamed ears were collected from each group, subjected to in situ immunofluorescence staining and observed under fluorescence microscope. Our results revealed MSCCXCR5 could be located in the inflamed ears of DTH mice.
Figure 10
Ear sampling for quantitative PCR analysis. Compared with DTH+MSCs group, levels of anti-inflammatory cytokines (IL-10) elevated in DTH+MSCCXCR5 group, while levels of pro-inflammatory cytokines (IL-4, TNF-α, IFN-γ, IL-6 and IL-17) decreased in DTH+MSCCXCR5 group. In a word, MSCCXCR5 displayed greater immunoregulatory effect.
Figure 11
Figure 12
After injection, MSCCXCR5 displayed better treatment efficacy than MSCeGFP, characterized by their abilities to decrease ear thickness and leukocyte infiltration. MSCCXCR5 significantly attenuated DTH as early as 24 hours post-injection, and had even greater effects at 48 hours post-injection. In a word, MSCCXCR5 regulated immune system in inflammatory condition in a more significant way.
Sequence and FeaturesAssembly Compatibility:- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 228
Illegal BamHI site found at 771 - 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
- 10